Core Viewpoint - Co-Diagnostics, Inc. reported a quarterly loss of $0.23 per share, which was better than the Zacks Consensus Estimate of a loss of $0.25, indicating an earnings surprise of +8.00% [1] Financial Performance - The company posted revenues of $0.16 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 45.67%, and a significant decline from $2.66 million in the same quarter last year [2] - Over the last four quarters, Co-Diagnostics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $0.3 million, and for the current fiscal year, it is -$0.68 on revenues of $0.95 million [7] Stock Performance - Co-Diagnostics shares have declined approximately 64.9% since the beginning of the year, contrasting with a 10% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Core Viewpoint - Natural Gas Services (NGS) shares have increased by 6.8% recently, with analysts suggesting a potential upside of 41.7% based on a mean price target of $36.25 [1][11]. Price Targets - The average price target for NGS ranges from a low of $32.00 to a high of $45.00, with a standard deviation of $5.97, indicating variability among analysts [2]. - The lowest estimate suggests a 25.1% increase, while the highest points to a 75.9% upside [2]. Analyst Sentiment - There is strong agreement among analysts regarding NGS's ability to report better earnings, which supports the expectation of an upside [4][11]. - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 5.7%, with no negative revisions [12]. Zacks Rank - NGS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction indicated by these targets appears to be a useful guide for potential price movement [14].

Group 1 - INPLAY OIL CP reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.26 per share, representing an earnings surprise of -80.77% [1] - The company posted revenues of $66.23 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.11%, compared to year-ago revenues of $30.3 million [2] - The stock has added about 9% since the beginning of the year, while the S&P 500 has gained 10% [3] Group 2 - The earnings outlook for INPLAY OIL CP is mixed, with the current consensus EPS estimate for the coming quarter at $0.17 on $64.01 million in revenues, and $0.56 on $220.02 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Oil and Gas - Exploration and Production - Canadian is currently in the top 25% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Company Performance - Oncobiologics reported a quarterly loss of $0.44 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, but an improvement from a loss of $0.83 per share a year ago, indicating a year-over-year improvement in losses [1] - The company posted revenues of $1.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 40.98%, compared to zero revenues a year ago [2] - Over the last four quarters, Oncobiologics has surpassed consensus EPS estimates two times [2] Stock Performance - Oncobiologics shares have increased by approximately 12.7% since the beginning of the year, outperforming the S&P 500's gain of 10% [3] - The current Zacks Rank for Oncobiologics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.33 on revenues of $5.78 million, and for the current fiscal year, it is -$1.89 on revenues of $6.42 million [7] - The outlook for the Medical - Biomedical and Genetics industry, in which Oncobiologics operates, is currently in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Group 1 - VYNE Therapeutics Inc. reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +43.48% [1] - The company posted revenues of $0.07 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31%, and a decline from $0.2 million in the same quarter last year [2] - VYNE Therapeutics shares have decreased by approximately 89.6% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $0.15 million, and for the current fiscal year, it is -$0.94 on revenues of $0.6 million [7] - The Medical - Drugs industry, to which VYNE Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Company Performance - CI&T Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and up from $0.03 per share a year ago, representing an earnings surprise of +16.67% [1] - The company posted revenues of $117.19 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.61%, compared to year-ago revenues of $100.45 million [2] - Over the last four quarters, CI&T has surpassed consensus revenue estimates three times [2] Stock Performance - CI&T shares have declined approximately 18.3% since the beginning of the year, while the S&P 500 has gained 9.6% [3] - The current Zacks Rank for CI&T is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $123.91 million, and for the current fiscal year, it is $0.28 on revenues of $479.2 million [7] - The outlook for the Internet - Software industry, where CI&T operates, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

分组1 - ReNew Energy Global PLC (RNW) reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, and showing a significant improvement from break-even earnings per share a year ago, resulting in an earnings surprise of +45.45% [1] - The company achieved revenues of $480 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 16.90%, and compared to year-ago revenues of $299 million, indicating strong revenue growth [2] - ReNew Energy Global shares have increased approximately 10.1% since the beginning of the year, outperforming the S&P 500's gain of 9.6% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $465.9 million, and for the current fiscal year, it is $0.26 on revenues of $1.59 billion [7] - The Alternative Energy - Other industry, to which ReNew Energy Global belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Red Robin (RRGB) reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of a loss of $0.25 per share, and showing improvement from a loss of $0.48 per share a year ago, resulting in an earnings surprise of +204.00% [1] - The company posted revenues of $283.7 million for the quarter ended June 2025, which was a miss against the Zacks Consensus Estimate by 0.53%, and a decline from year-ago revenues of $300.15 million [2] - Red Robin shares have increased by approximately 12.2% since the beginning of the year, outperforming the S&P 500's gain of 9.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.78 on revenues of $265.2 million, and for the current fiscal year, it is -$1.12 on revenues of $1.22 billion [7] - The estimate revisions trend for Red Robin was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Retail - Restaurants industry, to which Red Robin belongs, is currently ranked in the bottom 25% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8]

Core Insights - Xos, Inc. reported a quarterly loss of $0.91 per share, better than the Zacks Consensus Estimate of a loss of $1.06, and an improvement from a loss of $1.23 per share a year ago, resulting in an earnings surprise of +14.15% [1] - The company generated revenues of $18.39 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 40.51%, compared to $15.53 million in the same quarter last year [2] - Xos shares have increased approximately 4% year-to-date, while the S&P 500 has gained 9.6% [3] Earnings Outlook - The future performance of Xos stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.94 on revenues of $18.04 million, and for the current fiscal year, it is -$4.10 on revenues of $56.21 million [7] Industry Context - The Automotive - Domestic industry, to which Xos belongs, is currently ranked in the bottom 27% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - Thryv Holdings, Inc. (THRY) is positioned as a strong investment opportunity due to its improving earnings outlook and rising analyst estimates [1][2]. Earnings Estimate Revisions - Analysts have shown growing optimism regarding Thryv's earnings prospects, leading to a trend in estimate revisions that is expected to positively impact the stock price [2]. - The earnings estimate for the current quarter is $0.43 per share, reflecting a significant increase of +116.2% compared to the previous year [5]. - For the full year, the earnings estimate stands at $1.38 per share, indicating a remarkable change of +169.0% from the year-ago figure [6]. - Over the past month, the consensus estimate for the current year has increased by 26.98% due to one upward revision and no negative revisions [6][7]. Zacks Rank and Performance - Thryv currently holds a Zacks Rank 2 (Buy), which is indicative of promising estimate revisions and suggests potential for outperformance [8]. - Historically, stocks with a Zacks Rank 1 (Strong Buy) and 2 (Buy) have significantly outperformed the S&P 500 [8]. Stock Performance - The stock has gained 13.6% over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects [9].